C oronary heart disease (CHD) remains the leading cause of death in the industrialized world and will soon become so worldwide (1) . Much research has focused on biological risk factors and developing medicines to modify them. However, remarkably few medicines (e.g., aspirin, statins, and antihypertensive agents) are proven to reduce CHD risk.
In several recent, large-scale, randomized-controlled trials, newly-developed medicines (e.g., dalcetrapib and darapladib) showed no benefit over placebo in reducing risk for coronary events (2) (3) (4) . Often, these late-stage failures come after decades of research effort. Why were these results not anticipated? Two reasons stand out (5) . First, the field has traditionally depended on in vitro or animal models; however, preclinical disease models often have limited ability to predict benefit in patients. For example, atherosclerosis in humans is the result of genetic makeup and decades of atherogenic stimuli; it is not surprising that this is difficult to recapitulate in cells or in nonhuman model organisms. Second, drugs that block a specific gene target are sometimes taken for many years; we often do not know the effect over such an extended period.
How can we more accurately anticipate whether a medicine will reduce risk for clinical CHD without adverse effects? In this issue of the Journal, Ference et al. (6) show that the human genome may be a valuable tool for prioritizing molecular targets in drug development. Medicines are typically designed to target a specific gene and its protein product. There is naturally occurring variation in nearly every gene, some of which resides in a specific drug's target gene. Ezetimibe lowers plasma levels of low-density lipoprotein cholesterol (LDL-C) by blocking the Niemann-Pick C1-like 1 (NPC1L1) protein, a transporter allowing dietary cholesterol to enter the body from the intestinal lumen (7) . Experiments in cells and mice confirmed that ezetimibe tightly binds to and blocks NPC1L1, and targeted deletion of Npc1l1 in mice lowered plasma cholesterol and reduced atherosclerosis (8, 9) . In human volunteers, ezetimibe treatment None identified yet 
